FDA Authorizes ProSense Cryoablation System for Early-Stage Breast Cancer in Older Women
The FDA has granted marketing authorization for the ProSense Cryoablation System by IceCure for the treatment of small, early-stage breast cancer in women aged 70 and above who are not suitable for surgery, offering a minimally invasive care option. The announcement was made on October 3, 2025, by IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure […]